January 31, 2019

PPMD Kicks Off 2019 End Duchenne Tour in Las Vegas

PPMD is excited to kick off our 2019 End Duchenne Tour in Las Vegas this weekend! Combining each of the pillars that make up PPMD’s mission, the End Duchenne Tour brings updates on research, advocacy,…

Learn More

January 29, 2019

PPMD Designates Children’s Hospital of The King’s Daughters a Certified Duchenne Care Center

Today Parent Project Muscular Dystrophy (PPMD) named Children’s Hospital of The King’s Daughters (CHKD) the 23rd Certified Duchenne Care Center. PPMD’s Certified Duchenne Care Center Program, which supports standardized, comprehensive care and services for all people living…

Learn More

January 25, 2019

WATCH: Translarna® (ataluren) Development Update – Webinar Recording

On January 16, 2019, PTC Therapeutics joined Parent Project Muscular Dystrophy for a webinar update to provide the community with an overview of the Translarna development program with a focus on clinical trials that are…

Learn More

January 24, 2019

PPMD Awards $105,000 Grant to Explore A Mini-Dystrophin Gene Aimed at Protecting Cardiac Function

PPMD is excited to award the University of Missouri School of Medicine a grant for $105,000 to continue development of a minimized dystrophin gene aimed at protecting cardiac function in people with Duchenne. The project is led by Dongsheng…

Learn More

January 22, 2019

Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA

Capricor Therapeutics announced that it had positive outcomes in its comprehensive multidisciplinary meeting with the FDA regarding development of the company’s novel cell therapy candidate, CAP-1002, after being placed on voluntary hold last month. To…

Learn More

January 17, 2019

Parent Project Muscular Dystrophy Publishes 10 Year Registry Report

PPMD is excited to announce the release of the Ten Year Registry Report. This report is the culmination of data provided by registrants in The Duchenne Registry, as well as collaborative work with expert clinicians…

Learn More

January 15, 2019

Relive the Magic from the Disney Marathon Weekend

Four days of races, 48.6 miles, over $400,000 raised…plus new friends made and countless memories created – it was an amazing Walt Disney World Marathon Weekend for our entire Race to End Duchenne team! From…

Learn More

January 8, 2019

Meeting Update: Inflammation in Duchenne

Last month, PPMD convened a day and half meeting – Inflammation in Duchenne: Current and New Treatment Strategies – to bring academic and clinical researchers together to discuss advancements that could be made by treating…

Learn More

January 3, 2019

Wave Life Sciences Duchenne Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program

Wave Life Sciences announced that the planned Phase 2/3 efficacy and safety trial for its lead Duchenne clinical program has been selected for the U.S. Food and Drug Administration (FDA) pilot program for complex innovative…

Learn More

January 3, 2019

Catabasis Phase 3 PolarisDMD Trial for Edasalonexent Update & Additional Trial Sites Open for Enrollment

Catabasis Pharmaceuticals shared an update on clinical trial sites in the United States and recent international clinical trial application approvals to perform the Phase 3 PolarisDMD trial for edasalonexent (CAT-1004) in Duchenne. PolarisDMD clinical trial…

Learn More